Global bioeconomy in the spotlight12 interactive workshops, five plenary sessions and more than 3,000 registered attendees – last week the Global Bioeconomy Summit brought together international experts to discuss major trends and d … more ➔
A pioneering real AI drug discovery technologyThe current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and … more ➔
Collaborating to accelerate vaccine manufacturingDevelopment of the large-scale vaccine production process remains an inherently challenging undertaking. Given this complexity, it is more important than ever for vaccine manufacturers to collaborate … more ➔
3,000+ experts discuss bioeconomy globallyMore than 3,000 attendees are participating in the Global Bioeconomy Summit, currently taking place virtually until 20th November. Today, the plenary program and the livestream of the conference kicked-off. more ➔
EU COVID-19 antibody ready for clinical trialsAs investments into COVID-19 therapeutics is no EU priority, development is lagging behind the US. Now, CORAT Therapeutics candidate COR101 is set to enter clinical testing. more ➔
COVID-19: Moderna reports promising interim resultsAfter BioNTech SE reported that its COVID-19 vaccine candidate BNT162b2 was over 90% efficient in a Phase III trial, Moderna Inc announced an efficacy of 94.5%. more ➔
Evotec expanding at Milton Park campus Evotec SE is set to expand the company’s existing campus in Milton Park/Abingdon, UK, into a major, fully-integrated drug discovery and development centre. more ➔
Pfizer/BioNTech sign vaccine contract with EC Pfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of their mRNA-based COVID-19 vaccine candidate. more ➔
1,800+ experts will join the Global Bioeconomy SummitMore than 1,800 attendees already registered for the Global Bioeconomy Summit 2020. The conference takes place virtually from November 16 to 20. more ➔
BioNTech reports high efficacy of COVID-19 vaccineInterim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% – 30% better than required by the FDA. more ➔
